Objective: It is important to find optimal regimens of cisplatin (CDDP)-based third-generation chemotherapy and radiotherapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC). Methods: This Phase II study was designed to determine the toxicity and efficacy of two courses of chemotherapy (CDDP 80 mg/m 2 on day 1 and irinotecan 60 mg/m 2 on days 1 and 8) followed by accelerated hyperfractionated thoracic radiotherapy (60 Gy/40 fractions in 4 weeks) combined with daily carboplatin (CBDCA) administration. CBDCA was administered at a target area under the plasma level-time curve of 0.4 Â (24 h creatinine clearance þ 25), according to Calvert's formula. Results: Twenty-six patients were enrolled in the study. The patients' median age was 63 years (range 40 -74 years) and included 22 males and 4 females. Seven patients were Stage IIIA and 19 were Stage IIIB. Twenty had a performance status (PS) of 1 versus six with a PS of 0. There was one treatment-related death due to sepsis and pneumonia associated with Grade 4 neutropenia and diarrhea during chemotherapy. Grade 3 or 4 neutropenia and diarrhea were observed in 14 and 5 patients, respectively. Toxicity of the radiotherapy was mild. There were 0 complete response and 13 partial responses, giving a response rate of 50.0%. Median survival time and 2-year survival were 16.4 months and 21.5%, respectively. This study was designed with Simon's two-stage design, and the response rate did not meet the criteria to proceed to the second stage and the study was terminated early. Conclusions: This regimen might be inactive for patients with unresectable Stage III NSCLC.
INTRODUCTION
Over the past 2 decades, a great number of clinical trials have gradually proven the benefits of a chemotherapeutic approach for treatment of unresectable non-small cell lung cancer (NSCLC) (1, 2) . In unresectable Stage III NSCLC, in which the tumor is apparently confined to the chest but is surgically unresectable, several randomized trials have shown that combinations of chemotherapy and thoracic radiotherapy have improved survival compared with radiotherapy alone (3 -6) . It is important to find optimal regimens of combined chemotherapy and radiotherapy and to evaluate the feasibility and efficacy of those combinations.
Irinotecan (CPT-11) is an antitumor agent which inhibits the nuclear enzyme topoisomerase I (7, 8) . CPT-11 has played a significant role in the development of chemotherapy for NSCLC since the initial reports of its efficacy as a single agent (9, 10) . Combination chemotherapy of CPT-11 and cisplatin (CDDP), which is also a commonly used agent for NSCLC, is a promising regimen for NSCLC, as its high antitumor activity and manageable toxicity have been reproducibly reported (11, 12) . One critical but uncommon toxicity of CPT-11 is reported to be pulmonary toxicity (10) , and it is necessary to clarify how the chemotherapy regimen should be combined with thoracic radiotherapy in patients with Stage III NSCLC.
In addition to combined radio-chemotherapy, concomitant treatment with low doses of radiosensitizers has also been investigated in patients with Stage III NSCLC. Schaake-Koning et al. (13) reported that daily low-dose CDDP combined with thoracic radiation improved the local control of tumors in a randomized study. Furthermore, its favorable results were also confirmed in another Phase II study (14) . Carboplatin (CBDCA) has also been investigated as a radiosensitizer (15) . It has been suggested that CBDCA may be superior to CDDP in this role because it would provide a greater platinum concentration within cells at the time of irradiation (16) . We have reported the concurrent daily CBDCA (25 mg/m 2 ) and accelerated hyperfractionated thoracic radiotherapy (AHRT) in locally advanced NSCLC (17) . Of the 31 patients, the response rate was 84% (26/31) and the median survival time (MST) was 9.8 months. Major acute toxicity (Grade !3) included 55% with leukopenia, 16% with thrombocytopenia and 23% with esophagitis. Area under the plasma level -time curve (AUC) of CBDCA was significantly correlated with efficacy and leukopenia. In this setting, we concluded that daily CBDCA AUC of 0.4 plus concurrent AHRT was the most effective and safe treatment in locally advanced NSCLC.
On the other hand, the CDDP plus CPT-11 regimen is one of the standard platinum-based combination chemotherapies including a new agent in Stage IIIB/IV NSCLC in Japan (11) . Therefore, in order to improve therapeutic outcome in patients with unresectable Stage III NSCLC, we have conducted a Phase II study of a regimen of two courses of CDDP plus CPT-11 as an induction chemotherapy, followed by AHRT with daily low-dose CBDCA administration.
PATIENTS AND METHODS

PATIENT SELECTION
Patients with histologically or cytologically confirmed unresectable Stage III NSCLC who had not received cancer therapy were enrolled in this study. Staging for entry criteria was performed according to the lung cancer staging system of the International Union against Cancer. Staging procedures included chest X-ray, computed tomography (CT) scan of the chest, CT scan or magnetic resonance imaging of the brain, CT scan or ultrasound of the abdomen and isotope bone scanning. N-status was mainly based on size criteria in chest CT scan. Patients with pleural or pericardial effusion were excluded from the study. Each patient was required to meet the following criteria: Eastern Cooperative Oncology Group performance status (PS) of 0 or 1; ,75 years of age; predicted area of radiation field is less than half of one lung; adequate hematological, pulmonary, renal and hepatic function, i.e. white blood cell (WBC) count !4000/mL, hemoglobin level !10 g/dl, platelet count !130 000/mL, PaO 2 !70 torr, blood urea nitrogen and serum creatinine level no higher than the upper limit of normal, creatinine clearance (Ccr) !60 ml/min, serum total bilirubin level 1.5 mg/dl and serum glutamic oxaloacetic transaminase (GOT) and glutamic pyruvic transaminase (GPT) levels less than twice the upper limit of normal.
Patients with uncontrolled heart failure or infection, chronic pulmonary disease which restricts thoracic radiation, prolonged diarrhea, ileus, gastrointestinal bleeding or history of myocardial infarction in the last 3 months were excluded from the study. Female patients in pregnancy or lactation during chemotherapy were also excluded. All patients were required to give their own written informed consent.
TREATMENT SCHEDULE
After enrollment in the study, the patients received chemotherapy consisting of intravenous infusion of 80 mg/m 2 of CDDP on day 1 and 60 mg/m 2 of CPT-11 on days 1 and 8. The chemotherapy was repeated 3 -4 weeks after the start of the first course, as long as the patients had sufficiently recovered from toxicity. The chemotherapy was to be performed for two courses, unless unacceptable toxicity or disease progression occurred.
Four weeks after the start of the second course of chemotherapy, thoracic radiotherapy was started. The initial opposing anterior -posterior treatment fields encompassed the primary tumor, the bilateral mediastinal lymph nodes and the ipsilateral hilar nodes. The supraclavicular nodes were included within the field when there was clinical evidence of their involvement. A 1.5 cm tumor-free margin was required. The fraction size delivered was 1.5 Gy, given twice per day, 5 days per week. Thus, the total radiation dose was 60 Gy in 40 fractions over 4 weeks. The methods for spinal block and boost after the first 30 Gy delivery was left to the discretion of the treating radiation oncologist. On each day of thoracic radiotherapy, the patients also received intravenous CBDCA. CBDCA was dosed to a target AUC of 0.4 Â (24 h Ccr þ 25), according to Calvert's formula (18) , and was administered intravenously over 15 min immediately before the first radiation of the day. The CBDCA AUC of 0.4 was determined based on our previous study (17) .
CPT-11 on day 8 was skipped if the WBC count was ,3000/mL, platelet count ,75 000/mL or Grade 2 or higher diarrhea or abdominal pain was seen. During chemotherapy, if the WBC count fell ,2000/mL or the neutrophil count Jpn J Clin Oncol 2009;39 (12) 785 dropped ,1000/mL, daily granulocyte colony-stimulating factor (G-CSF) was administered subcutaneously until the WBC count increased to !10 000/mL or was no longer clinically indicated. Radiotherapy and concomitant use of G-CSF was contraindicated. When the second course of CDDP plus CPT-11 was started, each patient was required to meet the following criteria: WBC count !4000/mL, neutrophil count !2000/mL, platelet count !130 000/mL, serum creatinine level 1.5 mg/dl, serum GOT and GPT levels Grade 0 or 1, Ccr !30 ml/min, body temperature ,38.08C and PS 0, 1 or 2. For patients receiving G-CSF, 3 days after discontinuation, patients were required to meet the aforementioned hematological toxicity criteria prior to starting the second course of CDDP plus CPT-11. If the second course was delayed 2 weeks or more due to toxicity, chemotherapy with CDDP plus CPT-11 and low-dose CBDCA was terminated and only radiotherapy was used. According to toxicities in the first course of chemotherapy, the dose of CDDP was reduced by 25% for Grade 4 leukopenia, Grade 4 neutropenia !7 days, Grade 3 thrombocytopenia, Grade 3 or 4 mucositis or Grade 2 or higher renal toxicity, and by 50% for Grade 4 thrombocytopenia. The dose of CPT-11 was reduced by 25% for Grade 3 or 4 diarrhea and administration of CPT-11 was terminated if Grade 2 or higher pulmonary toxicity was seen.
Criteria for starting AHRT with daily low dosage CBDCA administration were the same as mentioned above for the second course of CDDP plus CPT-11. Six weeks after initiation of the second course of chemotherapy, if the same criteria were not fulfilled, CBDCA administration was terminated. In that case, only radiotherapy was used.
During chemoradiation, if the WBC count fell ,2000/mL, neutrophil count ,1000/mL or platelet count ,50 000/mL, daily use of CBDCA was suspended and only radiotherapy was continued. After recovery from neutropenia, administration of CBDCA was restarted. In case of Grade 4 hematological toxicities, chemoradiation was to be terminated. However, if any toxicity improved Grade 2 or lower, only radiotherapy could be used. If the PaO 2 level decreased by 10 torr or more compared with baseline value, chemoradiation was suspended and if it returned to baseline, treatment could be started again carefully. If Grade 3 or 4 radiationrelated esophagitis was seen, chemoradiation was suspended but could be started again when this toxicity improved to Grade 2 or lower. If patients had a fever of 388C or higher, chemoradiation was suspended until they were afebrile. Chemoradiation was also suspended when deterioration of PS to 3 or 4 occurred, and PS 0, 1 or 2 was necessary to restart the protocol treatment.
TREATMENT EVALUATION
Tumor response and toxicity were evaluated according to World Health Organization response criteria (19) and Japan Clinical Oncology Group (JCOG) toxicity criteria (20) , respectively. Complete response (CR), partial response (PR) and no change (NC) were reviewed and confirmed by central review with chest radiographs or CTs at the regular disease-group meeting. Complete blood cell count and routine blood chemistry were checked twice a week, and arterial blood gas and chest radiographs were checked at least once a week, until the patient had apparently recovered from all acute toxic effects after the completion of the treatment. In this trial, the methods to follow-up the patient after the protocol treatment were not clearly defined. In addition, not only late toxicities but also recurrence patterns after finishing protocol treatment were not routinely recorded in the case report form (CRF). Therefore, the interval of evaluation for late toxicities was left to the discretion of the treating physician. Consequently, the frequency of visiting the doctors and radiologic examinations was heterogeneous among the patients.
STUDY DESIGN AND STATISTICAL METHODS
This trial was designed as a multicenter prospective single-arm Phase II study, and the study protocol was approved by the Clinical Trial Review Committee (protocol review committee) of JCOG (21) and the institutional review board of each participating institution before study activation. After pre-treatment staging and eligibility evaluation, patients were registered at the JCOG Data Center by telephone or fax. The study was performed by the JCOG Lung Cancer Study Group and all study data were managed by the JCOG Data Center.
The primary endpoints of this study were the overall response rate (ORR) and overall survival (OS). The ORR was defined as the proportion of the patients with CR or PR out of all eligible patients. The confidence intervals for the ORR were calculated based on the exact method. The OS was measured from the date of patient registration to the date of death due to any cause. If a patient was alive at the final follow-up survey, OS was censored at the last contact date. The estimates of survival distribution were calculated by the Kaplan -Meier method and confidence intervals were based on Greenwood's formula (22) . And 2-year OS was expected to be $40%. The progression-free survival was not measured in this study.
We set an expected level (P1) of response rate as 80%, threshold level (P0) as 60%, a-error level was 0.05 and b-error level was 0.10. We set the planned total sample size as 45 according to Simon's minimax two-stage design (23). If 15 or fewer patients out of 26 patients showed objective responses at the first stage, the study was to be terminated early. The OS was followed up to 20 months after the last enrollment.
RESULTS
PATIENT CHARACTERISTICS
Between February 1996 and January 1999, 26 patients from 5 institutions were enrolled in this study and all received induction chemotherapy. The pace of enrollment was approximately one-fourth of the planned one in the protocol.
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A Phase II study of chemoradiotherapy For the pre-specified first stage decision, the accrual was temporarily closed and the response rate was assessed. Characteristics of the 26 patients are listed in Tables 2  and 3 . In six patients, treatment was terminated after the first course of chemotherapy. The reasons for the withdrawal were disease progression in three patients and toxicity in three. In three patients with disease progression after the first course of CDDP plus CPT-11, one patient could receive sequential chemoradiation. In one patient Cre .1.5 mg/dl persisted, whereas in another patient, Grade 4 diarrhea, Grade 2 neutropenia and Grade 2 fever caused deterioration of PS and resulted in termination of induction chemotherapy. That patient died of sepsis and pneumonia from Grade 4 neutropenia and diarrhea which we categorized as treatment-related death. One patient had disease progression after two courses of chemotherapy and could not receive radiotherapy. One patient experienced Grade 4 leukopenia and the dose of CDDP in the second course should have been reduced to 75% of the original dosage. However, this patient received only CPT-11 and CDDP was improperly omitted in the second course, which was judged as a protocol violation. Delay in the start of the second course occurred in three patients. CPT-11 administration on day 8 was skipped in four patients and three patients had dose reduction of CPT-11 in the second course. The reason for dose omission or dose reduction was diarrhea in five patients. Twenty patients received thoracic radiotherapy according to the protocol but 3 of the 20 patients could not receive the whole 60 Gy of radiation with daily CBDCA because of hypoxemia, emesis or onset of herpes zoster in the radiation field in each patient, respectively. Radiotherapy could not be delivered for six patients. The reason for not receiving radiotherapy was disease progression in four patients and toxicity in two patients including treatment-related death in one patient. Of the 20 patients receiving radiotherapy, actual mean radiation dose and actual mean number of CBDCA infusion was 56.8 Gy and 17.5 times, respectively (Table 3) . Jpn J Clin Oncol 2009;39 (12) 787
TOXICITY
There was one treatment-related death due to septic shock and pneumonia associated with Grade 4 neutropenia, Grade 4 thrombocytopenia and Grade 4 diarrhea. That patient had CDDP and CPT-11 administration on day 1 and CPT-11 on day 8 in the first course and suffered from serious toxicity. Pseudomonous aeruginosa was detected in the microbiological culture test from the stool of the patient. This patient died on day 35 from toxicities mentioned above. Toxicities in the 26 patients are listed in Table 4 . Grade 3 or 4 neutropenia occurred in 54% of the patients. Grade 3 or 4 thrombocytopenia occurred in four patients and one patient required platelet transfusion.
The most frequent non-hematological toxicity was diarrhea, and Grade 2 or more occurred in 46% of the patients. Five patients had Grade 2 esophagitis during radiotherapy but it did not cause termination of the therapy. Pulmonary toxicity was not evident during the radiotherapy, as well as CPT-11 including chemotherapy. In one patient, radiotherapy was terminated due to a decrease in arterial oxygen pressure by 17 torr when compared with baseline but that patient also had disease progression during the therapy and it was difficult to evaluate the causal relationship to the protocol treatment. In this trial, late toxicities after finishing protocol treatment were not routinely recorded in CRF.
RESPONSE AND SURVIVAL
Objective tumor response is summarized in Table 5 . Among the 26 patients, there were 13 PRs and 0 CR, giving a response rate of 50% (95% confidence interval, 30 -70%). In 10 patients, a PR was achieved before the start of radiotherapy. Disease progression occurred during chemotherapy in four patients, who had to terminate the protocol treatment. Tumor response could not be evaluated in the patient with treatment-related death. The response rate at the first stage did not meet the criteria to proceed to the second stage and the study was terminated early. Figure 1 shows the OS curve of all patients enrolled in the study. After follow-up for 20 months after the last enrollment, the MST was 16.4 months. The 1-and 2-year survival rates in the 26 patients were 65.4% and 21.5%, respectively.
DISCUSSION
The findings of the present study suggest several important points that should be applied in future studies of Stage III NSCLC, although the response rate of this combination therapy was not as high as expected. First, the protocol regimen may not be sufficiently optimized in order to keep high compliance. The inferior tumor response and the high frequency of disease progression during the induction chemotherapy with CPT-11 and CDDP appeared to be the major reason for the disappointing results, which led to the early termination of the present study. Only 10 out of the 26 patients showed .50% tumor reduction during chemotherapy. It appeared unsatisfactory when one considers (24, 25) . This case distribution might have contributed to the poor outcome of this study.
In the view of toxicity management, diarrhea is considered to be key toxicity to be managed carefully in combination chemotherapy using CPT-11. Relative dose intensity of CDDP, CPT-11 and radiotherapy was acceptable in this protocol; however, severe diarrhea caused lowering protocol compliance probably because high-dose loperamide therapy (26) even in the case of severe diarrhea was not used during initial period in this study. It might be possible that the antidiarrhea agent was inadequate and protocol treatment could not be completed in some cases as a result. Had high-dose loperamide therapy been applied appropriately in all eligible cases, better response rate and survival might have been achieved in this study.
It is noteworthy that the strong association between CPT-11 delivery and antitumor response was seen in the present study. In fact, among the 12 patients who had two courses of induction chemotherapy without any delay, omission or dose reduction in CPT-11 administration, 7 showed .50% tumor reduction during the induction chemotherapy and 9 eventually achieved PR after the whole course of therapy (data not shown). This result suggests the possibility that the schedule of CPT-11 administration in this study (days 1 and 8) which was different from the more common regimen (days 1, 8 and 15) may explain the relatively low response rate and the large number of patients with disease progression. Six patients could not receive the protocol radiotherapy because of disease progression or toxicity of the induction chemotherapy. Planned omission of CPT-11 administration on day 15 was intended to reduce risk of pulmonary toxicity during radiotherapy but it might cause unsatisfactory tumor response in the chemotherapy.
Second, the timing of combination of thoracic radiation with chemotherapy may also not be optimized. The present study adopted sequential radiation following induction chemotherapy with CPT-11 and CDDP but suggests that inferior antitumor activity in the chemotherapy could cause failing to receive radiotherapy in some patients. It is difficult to find the best regimen using CPT-11 in the combined modality treatment for Stage III NSCLC.
Because late toxicities were not fully evaluated, the occurrence of both pneumonitis and delayed esophagitis might be possibly underestimated in this study. However, despite the high radiation dose, acute esophagitis were very mild contrary to our expectation, although we cannot clearly explain the reason. Most patients who could proceed to chemoradiotherapy could complete the scheduled radiation with acceptable toxicity. The MST of 16.4 months in the present study was almost as good as in other studies that showed high response rates and survival benefit in Stage III NSCLC.
Although our study was prematurely closed after interim analysis because of low response rate, OS which was one of the primary endpoints was comparable with other literatures (24, 25, 27) . In our opinion, AHRT with CBDCA still remains a chemoradiotherapeutic option and should be investigated further with combinations of other chemotherapy regimens.
In recent years, however, some articles have shown that addition of induction chemotherapy before concurrent chemoradiotherapy adds toxicity and provides no survival benefit (24, 25) . In addition, National Comprehensive Cancer Network (NCCN) practice guideline recommends CDDP plus etoposide or vinblastin with concurrent radiotherapy as preferred standard of cares (category 2A) for patients with unresectable NSCLC (28) . Further studies to investigate the role of induction chemotherapy followed by chemoradiotherapy may be not necessary until appearance of more active anticancer agents.
In conclusion, we failed to demonstrate promising efficacy of this regimen, and the development of a brand-new treatment strategy for combining chemotherapy with radiotherapy is necessary for the improvement of the prognosis of the patients with unresectable Stage III NSCLC.
